BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32929175)

  • 1. Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide: novel strategy for haploidentical transplant in sickle cell disease.
    Kharya G; Bakane A; Agarwal S; Rauthan A
    Bone Marrow Transplant; 2021 Feb; 56(2):492-504. PubMed ID: 32929175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease.
    Pawlowska AB; Cheng JC; Karras NA; Sun W; Wang LD; Bell AD; Gutierrez L; Rosenthal J
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):185-189. PubMed ID: 28939451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretransplant myeloid and immune suppression, reduced toxicity conditioning with posttransplant cyclophosphamide: Initial outcomes of novel approach for matched unrelated donor hematopoietic stem cell transplant for hemoglobinopathies.
    Kharya G; Bakane AN; Rauthan AM
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28909. PubMed ID: 33470527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
    Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide.
    Mallhi KK; Srikanthan MA; Baker KK; Frangoul HA; Torgerson TR; Petrovic A; Geddis AE; Carpenter PA; Baker KS; Sandmaier BM; Thakar MS; Skoda-Smith S; Kiem HP; Storb R; Woolfrey AE; Burroughs LM
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1332-1341. PubMed ID: 32234377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative.
    de la Fuente J; Dhedin N; Koyama T; Bernaudin F; Kuentz M; Karnik L; Socié G; Culos KA; Brodsky RA; DeBaun MR; Kassim AA
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1197-1209. PubMed ID: 30500440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor-Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Comparative Study.
    Jaiswal SR; Bhakuni P; Joy A; Murli N; Bharadwaj P; Zaman S; Nedunchezian M; Chakrabarti S
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):542-548. PubMed ID: 29191663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
    Duléry R; Bastos J; Paviglianiti A; Malard F; Brissot E; Battipaglia G; Médiavilla C; Giannotti F; Banet A; de Wyngaert ZV; Ledraa T; Belhocine R; Sestili S; Adaeva R; Lapusan S; Isnard F; Legrand O; Vekhoff A; Rubio MT; Ruggeri A; Mohty M
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1407-1415. PubMed ID: 30871978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.
    Rangarajan HG; Abu-Arja R; Pai V; Guilcher GMT; Soni S
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):413-417. PubMed ID: 29061531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.
    Bolaños-Meade J; Cooke KR; Gamper CJ; Ali SA; Ambinder RF; Borrello IM; Fuchs EJ; Gladstone DE; Gocke CB; Huff CA; Luznik L; Swinnen LJ; Symons HJ; Terezakis SA; Wagner-Johnston N; Jones RJ; Brodsky RA
    Lancet Haematol; 2019 Apr; 6(4):e183-e193. PubMed ID: 30878319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haploidentical Allogeneic Stem Cell Transplantation in Sickle Cell Disease: A Systematic Review and Meta-Analysis.
    Aydin M; Dovern E; Leeflang MMG; de la Fuente J; Kassim AA; Biemond BJ; Nur E
    Transplant Cell Ther; 2021 Dec; 27(12):1004.e1-1004.e8. PubMed ID: 34537420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
    Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haploidentical Hematopoietic Stem Cell Transplantation in Thalassemia.
    Anurathapan U; Pakakasama S; Songdej D; Pongphitcha P; Chuansumrit A; Andersson BS; Hongeng S
    Hemoglobin; 2022 Jan; 46(1):2-6. PubMed ID: 35920292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
    Abraham A; Cluster A; Jacobsohn D; Delgado D; Hulbert ML; Kukadiya D; Murray L; Shenoy S
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1587-1592. PubMed ID: 28578010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe.
    Gluckman E; Cappelli B; Scigliuolo GM; De la Fuente J; Corbacioglu S
    Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):181-188. PubMed ID: 32201153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children.
    Medina D; Estacio M; Rosales M; Manzi E
    Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):208-213. PubMed ID: 32224144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.
    Ciurea SO; Zhang MJ; Bacigalupo AA; Bashey A; Appelbaum FR; Aljitawi OS; Armand P; Antin JH; Chen J; Devine SM; Fowler DH; Luznik L; Nakamura R; O'Donnell PV; Perales MA; Pingali SR; Porter DL; Riches MR; Ringdén OT; Rocha V; Vij R; Weisdorf DJ; Champlin RE; Horowitz MM; Fuchs EJ; Eapen M
    Blood; 2015 Aug; 126(8):1033-40. PubMed ID: 26130705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using a Novel Conditioning Regimen.
    Anurathapan U; Hongeng S; Pakakasama S; Songdej D; Sirachainan N; Pongphitcha P; Chuansumrit A; Charoenkwan P; Jetsrisuparb A; Sanpakit K; Rujkijyanont P; Meekaewkunchorn A; Lektrakul Y; Iamsirirak P; Surapolchai P; Sirireung S; Sruamsiri R; Wahidiyat PA; Andersson BS
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1106-1112. PubMed ID: 31931116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.